GynecologyGynecology2079-56962079-5831Consilium Medicum3347010.26442/20795696.2019.4.190564Research ArticleEvaluation of the effectiveness of adjuvant anti-progestogen therapy after conservative myomectomy in women of reproductive ageLebedevaYanina AHead of the Divisionyanina_simakova@mail.ruKovalenkoInna ICand. Sci. (Med.)innakov2010@yandex.ruMolchanovOleg LD. Sci. (Med.), Prof.moleg700@mail.ruBaibuzDmitrii VDeputy Directorbaybooz@mail.ruKulikovaNatalia Vdockulikova@rambler.ruSaint Petersburg State UniversityImmanuel Kant Baltic Federal University15082019214192316042020Copyright © 2019, Consilium Medicum2019Relevance. Due to the high prevalence of uterine fibroids in young women and the possible effect on reproductive potential, the development, implementation and application of the most benign treatment methods are a priority. Aim. To evaluate the effectiveness of adjuvant anti-progestogen therapy after conservative myomectomy in women of reproductive age. Materials and methods. A comparative analysis of the results of treatment of patients of reproductive age with uterine myoma has been carried out. Group 1 (n=38) included patients who underwent conservative myomectomy and/or hysteroresectoscopy without subsequent anti-relapse drug therapy. The average age is 31.5 years (4.6). Group 2 (n=43) included patients after conservative myomectomy who received mifepristone as anti-relapse therapy after surgery. The average age is 31.9 years (4.5). Results. Mifepristone therapy, as an adjuvant treatment after conservative myomectomy, can significantly reduce the risk of recurrence, stabilize the size of the uterus, reduce the severity of clinical manifestations in the form of pain syndrome and heavy menstruation associated with relapse, thereby improving the reproductive health of women. Conclusions. The use of adjuvant anti-progestogen therapy after conservative myomectomy in women of reproductive age is a very effective method for treating uterine fibroids and can be considered as a therapy of choice in such patients.conservative myomectomyuterine myomamifeprestonreproductive healthanti-progestogen therapyконсервативная миомэктомиямиома маткимифепристонрепродуктивное здоровьеантигестагенная терапия[Плеханов А.Н., Татарова Н.А., Рябинин Г.Б., Шишкина Ю.А. Восстановление репродуктивной функции у женщин после консервативной миомэктомии. Эффективная фармакотерапия. 2013; 18: 42-6.][Maruo T et al. Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas. Expert Opin. Drug Discov 2011; 6 (9): 897-911.][Андреева Е.Н., Рябинкина Т.С., Рыжова Т.Е. Минздрав настоятельно рекомендует. Обзор нового клинического протокола диагностики и лечения миомы матки. StatusPraesens. Гинекология, акушерство, бесплодный брак. 2016; 2 (31): 41-50.][Радь Я.Н., Дуглас Н.И. Современный подход к лечению миомы матки у женщин раннего репродуктивного возраста в РС(Я). Национальная ассоциация ученых. 2016; 1 (17): 115-7.][Миома матки: диагностика, лечение и реабилитация. Клинические рекомендации (протокол лечения). М.: Минздрав России, 2015.][Тоноян Н.М. и др. Рецидивы миомы матки. современный взгляд на проблемы диагностики, лечения и прогнозирования. Акушерство и гинекология. 2019; 3: 32-8.][Radosa M.P, Owsianowski Z, Mother A, Runnebaum I.B. Long-term risk of fibroid recurrence after laparoscopic myomectomy. Eur J Obstet Gynecol Reprod Biol 2014, 180 (1): 1-2]